$BCDA News

BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities

BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US

What's Going On With BioCardia Stock Tuesday?

HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target

BioCardia Announces $4.4 Million Financing

BioCardia Sells 3,509,604 Shares At Average Price Of $1.279 On June 5; No Warrants Issued In Capital Raise

Why Did BCDA Stock Surge More Than 50% Today?

BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA)

FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF

Why Is BioCardia Stock Gaining Friday?

BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction

BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

BioCardia (BCDA) Q1 2026 Earnings Transcript

BioCardia, Inc. Q1 2026 Earnings Call Summary

BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...

BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript

BioCardia Q1 2026 Earnings Call: Complete Transcript